Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)

Authors
Category Primary study
ConferenceOncology Research and Treatment
Year 2017
This article has no abstract
Epistemonikos ID: 77c8fe5a615195f4aaa3ef9f2f142154b2f9948b
First added on: Apr 29, 2026